2010 AnnuAl REpoRT - Ciberdem

More about CIBERDEM
The Centro de Investigación Biomédica en Red de Diabetes
y Enfermedades Metabólicas Asociadas (CIBERDEM)
is a public research consortium which was founded on
December 3rd 2007 and is financed by the Instituto de
Salud Carlos III (ISCIII) and the Ministerio de Ciencia e
Innovación (MICINN).
CIBERDEM is made up of 32 research groups based in
different hospitals, universities and research centres
throughout Spain. The main aim of CIBERDEM is to
promote research into diabetes and associated metabolic
disorders, identifying the genes which predispose to these
diseases and the environmental factors which contribute to
their development; to discover the molecular mechanisms
involved in the alteration of insulin secretion and signalling; to
determine the molecular and cellular mechanisms involved
in the formation and destruction of pancreatic beta cells;
to study strategies for substitution of this cell mass; and
to investigate the signals which link obesity and diabetes.
Of special interest is research into the complications of
diabetes and associated metabolic disorders.
CIBERDEM is divided into three research areas:
Area 1. Insulin signalling and resistance. Role in the onset
of diabetes
Area 2. Dyslipidaemia, metabolic syndrome and
microvascular complications of diabetes
Area 3. Islet dysfunction, destruction and regeneration.
Autoimmunity. Impact on the pathogenesis of diabetes
Research Areas
Area 1
Area 2
Area 3
Steering Committee
Technological Platforms
Biobank
Metabolomics Platform
CIBERDEM’s organization chart.
Management Committee
Permanent Commission
Scientific Director
Adjunct Scientific Director
External Scientific Committee
Managing Director
Management Office
The nature, goals and financing of CIBERDEM are
enshrined in its statutes, published in the Boletín Oficial
del Estado (BOE) number 49, of February 26th, 2008. The
approval of CIBERDEM’s new statutes on May 14th 2010
brings, amongst other things, a change in the organization
of its scientific activity: where before there were scientific
areas, there are now programmes. These changes will
become apparent in 2011. The main governing bodies of
CIBERDEM are as follows:
Management Committee
This is made up of three representatives of the Instituto de
Salud Carlos III and one representative from each of the other
bodies in the consortium; it is the supreme governing body of
CIBERDEM and exercises general control over the organization.
President
José J. Navas, Director of the Instituto de Salud Carlos III
(ISCIII)
Members
Pascual Sanz, Consejo Superior de Investigaciones
Científicas (CSIC)
Rubén Moreno, Fundación Centro de Investigación Príncipe
Felipe
Juan Viña, Fundación Hospital Clínico Universitario de
Valencia
Emilià Pola, Fundación IDIBELL
Francesc Vidal, Fundació Institut d’Investigació Sanitària
Pere Virgili
José Luis de Sancho, Fundació Institut de Recerca Hospital
Universitari Vall d’Hebron
José Francisco Cañón, Fundación Instituto Mediterráneo
para el Avance de la Biotecnología Sanitaria
Emili Bargalló, Fundación para la Investigación y Docencia
Sant Joan de Déu
Juan Antonio Álvaro, Fundación Jiménez Díaz
Margarida Corominas, Fundació Privada Institut de Recerca
Biomèdica
Carmen Garaizar, Fundación Vasca de Innovación e
Investigación Sanitarias
Jaume Kulisevsky, Institut de Recerca Hospital de la Santa
Creu i Sant Pau
Pastora Martínez, Institut d’Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS)
Elena Andradas, Servicio Madrileño de Salud
Ana Ripoll, Universitat Autònoma de Barcelona
Xavier Meneses, Universitat de Barcelona
Carmen Acebal, Universidad Complutense de Madrid
Salvador Viniegra, Universidad Miguel Hernández
2010 Annual Report
15